Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Synovitis Clear all
Completed No phase listed Observational

Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients

NCT00001679
View directory record Official record
Conditions
Arthritis, Reactive, Arthritis, Rheumatoid, Synovitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

NCT00001677
View directory record Official record
Conditions
Arthritis, Rheumatoid, Synovitis
Interventions
Methotrexate, Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 6:57 AM EDT
Terminated Phase 1 Interventional

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530
View directory record Official record
Conditions
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions
PLX7486 TsOH
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 22, 2026, 6:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions
Vimseltinib, Placebo
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
9
States / cities
Palo Alto, California • Denver, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Recruiting No phase listed Observational

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

NCT04635111
View directory record Official record
Conditions
Hepatotoxicity, Tenosynovial Giant Cell Tumor
Interventions
TURALIO™
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
8
States / cities
Santa Monica, California • Whittier, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Not applicable Interventional

Treatment for Sacroiliac Joint Pain Using Platelet-rich Plasma (PRP) Versus Steroid/Anesthetic

NCT05121961
View directory record Official record
Conditions
Low Back Pain, Sacroiliac Joint Synovitis
Interventions
Sacroiliac intra-articular injection
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00425932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab
Biological
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

NCT04526704
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 22, 2026, 6:57 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ)

NCT01471418
View directory record Official record
Conditions
Temporomandibular Joint, Conservative Treatment Therapy
Interventions
PET/CT with 18-FDG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 22, 2026, 6:57 AM EDT
Active, not recruiting Phase 4 Interventional

Corticosteroid Meniscectomy Randomized Trial

NCT04641351
View directory record Official record
Conditions
Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions
Zilretta Injectable Product or Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 1 Interventional

Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients

NCT00014794
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
15-O labeled water
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

NCT04223635
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

NCT04731675
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
Interventions
AMB-05X
Biological
Lead sponsor
AmMax Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 22, 2026, 6:57 AM EDT
Recruiting No phase listed Observational

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

NCT05700682
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteo Arthritis Shoulders, Synovitis of Knee, Synovitis/Tenosynovitis - Hip, Synovitis, Pain, Chronic
Interventions
Shoulder/Hip/Knee Embolization with Embozene Microspheres
Device
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
25 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Results available

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

NCT03291288
View directory record Official record
Conditions
Drug Interaction Potential
Interventions
Tolbutamide, Midazolam, Pexidartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients

NCT01948388
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
corticotrophin 80 units
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 22, 2026, 6:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

NCT02471716
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Interventions
FPA008
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 22, 2026, 6:57 AM EDT
Completed No phase listed Observational

Accuracy of Pediatric Emergency Medicine Providers in Diagnosing Hip Effusions Using Point of Care Ultrasound

NCT05971745
View directory record Official record
Conditions
Hip Effusion, Septic Arthritis, Transient Synovitis, Hip
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
1 Month to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Hartford, Connecticut • New Haven, Connecticut • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 22, 2026, 6:57 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344
View directory record Official record
Conditions
Neoplasms, Tenosynovial Giant Cell Tumor
Interventions
ABSK021
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 6:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis

NCT00001375
View directory record Official record
Conditions
Arthritis, Arthritis, Reactive, Arthritis, Rheumatoid, Reiter's Disease, Synovitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 6:57 AM EDT
Terminated Phase 4 Interventional Results available

Lipogems Prospective Study

NCT03922490
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Lipogems Device PLUS debridement, Debridement only
Device · Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 22, 2026, 6:57 AM EDT